إعلان
إعلان
CBIO
Crescent Biopharma, Inc. Common Stock
10.81
USDبرعاية
-0.16
-1.41%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
بعد الإغلاق
10.80
-0.01
-0.09%
تقارير أرباح CBIO
النسبة الإيجابية المفاجئة
CBIO تفوق 29 من 38 آخر التقديرات.
76%
التقرير التالي
بيانات التقرير القادم
٠٩ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
$5.10M
/-$2.51
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/+97.64%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/--
Crescent Biopharma, Inc. Common Stock earnings per share and revenue
On ٠٦ نوفمبر ٢٠٢٥, CBIO reported earnings of -1.27 USD per share (EPS) for Q3 25, beating the estimate of -2.02 USD, resulting in a 37.18% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +5.39% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 المحللين forecast an EPS of -2.51 USD, with revenue projected to reach 5.10 مليون USD, implying an زيادة of 97.64% EPS, and -- of --% in Revenue from the last quarter.
الأسئلة الشائعة
What were Crescent Biopharma, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Crescent Biopharma, Inc. Common Stock reported EPS of -$1.27, beating estimates by 37.18%, and revenue of $0.00, 0% as expectations.
How did the market react to Crescent Biopharma, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 5.39%, changed from $12.43 before the earnings release to $13.10 the day after.
When is Crescent Biopharma, Inc. Common Stock expected to report next?
The next earning report is scheduled for ٠٩ فبراير ٢٠٢٦.
What are the forecasts for Crescent Biopharma, Inc. Common Stock's next earnings report?
Based on 8
المحللين, Crescent Biopharma, Inc. Common Stock is expected to report EPS of -$2.51 and revenue of $5.10M for Q4 2025.
Which companies are reporting earnings today?
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان